DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. on May 23, 2025. The filing addresses material definitive agreements regarding preferred stock lock-up extensions and amendments to the rights of Series A-1 and Series B-1 preferred stockholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity structure modifications rather than financial performance results.
Material Changes
- Lock-Up Agreement Extension: Between May 23, 2025, and May 28, 2025, the Company entered into an Amended and Restated Lock-Up Agreement with holders of Series B and Series C Preferred Stock. The restrictive period for these holders was extended until February 21, 2026.
- Incentive Structure: Holders who agree to the extended lock-up are entitled to receive an additional 10% of the common stock underlying their preferred shares. This is part of a broader program where holders can receive up to 40% additional shares over 12 months for agreeing not to transfer shares.
- Preferred Stock Amendments: On May 20, 2025, the Company amended the Certificates of Designation for Series A-1 and Series B-1 Preferred Stock. These amendments allow holders to request dividends and distributions in the form of pre-funded common stock purchase warrants instead of common stock shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The securities issued under the amended agreements are exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and may not be resold in the United States absent registration or an exemption.
Investor Verification Checklist
- Verify the specific terms of the Amended and Restated Lock-Up Agreement (Exhibit 10.1) to understand the exact conditions for the additional 10% share issuance.
- Review the Amended and Restated Certificates of Designation for Series A-1 and Series B-1 Preferred Stock (Exhibits 3.1 and 3.2) to confirm the mechanics of receiving pre-funded warrants versus common stock.
- Confirm the total number of shares underlying the Series B and Series C Preferred Stock to assess the potential dilution impact of the additional shares.
- Check subsequent filings for any impact on the Company's capitalization table or cash flow resulting from the shift to warrant-based dividends.